- Journalists Shed Light on Deadly Hantavirus Outbreak and a Crisis in the Nation’s ERs
- Is the horizon still bright for orthodontists?
- The Make America Healthy Again Movement Comes for Hospital Food
- What’s driving physicians to early retirement
- Why Tenet’s CEO says ASCs keep choosing USPI
- 12 recent hospital, health system president exits
- Hospitals embrace rapid opioid treatment in fentanyl era: Study
- Texas systems open 200-bed behavioral health center
- 32 health systems spending $5B on cancer care
- Sanford, North Memorial planned combination adds to Minnesota healthcare deal wave
- Lone Peak Dental Group acquires Arizona practice
- Inside Northwestern Medicine’s battle against surgeon burnout
- UT Austin launches Epic ahead of new academic medical center
- Ohio system names COO
- Buy, sell or fight: The new calculus of health system growth
- OpenAI’s growing healthcare footprint
- Tennessee optometrist pleads guilty to $6.9M Medicare fraud
- Why Cook County Health’s Medicaid coverage loss strategy is drawing attention
- Akron Children’s chosen for former Ohio college campus site
- Surgery Partners doubles down on orthopedics, robotics as total joint growth hits 14.6%
- The growing war over Anthem’s out-of-network penalty policy
- 3 PDS Health headlines to know in 1 week
- Remarks at the Conference on Financial Market Regulation
- Could ASCs help cardiology move past its ‘breaking point’?
- 3 programs expanding the anesthesia workforce in 2026
- Dad Jokes: Remarks at the 13th Annual Conference on Financial Markets Regulation
- UVM Health targets $300M in cuts, outpatient overhaul amid $280M deficit
- Maine behavioral health provider cites industry pressures in merger
- Dentists opening practices in 1 month
- The Aspen Group names new chief commercial officer
- RFK Jr. Launches Plan To Curb Antidepressant 'Overprescription'
- Georgia mental health provider adds after-hours outpatient program
- AI-augmented behavioral health provider Theris launches out of stealth
- 5 data breaches, settlements impacting cardiology
- Maine hospital adds stroke prevention, cardiac imaging services
- As new tech, AI sweeps the marketing world, Eversana Intouch’s new CEO is ‘comfortable in the gray’
- Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
- Trump plans to fire FDA chief Marty Makary: report
- Trump plans to fire FDA chief Marty Makary: report
- Oregon governor signs behavioral health workforce expansion bills amid shortage
- Remarks at the Special Competitive Studies Project AI+ Expo
- Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
- 5 DSOs making headlines
- Plant-Based Foods May Help Lower Risk of High Blood Pressure
- The ACA exchanges dominated Q1 earnings calls. Here's what payer, health system execs had to say
- Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
- Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'
- Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma
- Op-ed: It's time to make more strategic bets on AI in healthcare
- Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
- Super Shoes Might Increase Risk Of Running Injuries, Study Says
- TV, Movies Offer Flawed Depictions Of Autism, Add To Delayed Diagnosis, Study Says
- Opioid OD Survivors Have Triple Rate Of Repeat Overdoses Than Previously Estimated
- Revisiting Pharma’s tariff reality
- A New Medicare Option For Weight Loss Drugs: What Older Americans Should Know
- Exposure Therapy Can Successfully Ease Peanut Allergies
- Listen: A Federal Agency Is After Workers’ Health Data, and Critics Are Alarmed
- In California Governor Race, Single-Payer Is a Litmus Test. There’s Still No Way To Pay for It.
- AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
- Johnson & Johnson launches ‘Generation Fine’ depression project
- Pre-launch efforts linked to lasting drug awareness edge: report
- GSK tees up a Modern Family for meningitis messaging
- NYC invests $12M in overdose recovery workforce
- Aspen Dental to pay $2M to settle allegations of violating corporate dentistry laws
- Texas dental practice relocates into 6K-square-foot facility
- Medit launches global orthodontics division, acquires California training institute
- Pennsylvania enacts dental faculty bill
- Cruise Ship Hantavirus Outbreak Kills 3 as WHO Says Risk Is Low
- How policy, reimbursement incentives, could help healthcare address its climate footprint
- Remarks at the 13th Annual Conference on Financial Market Regulation
- 5 best practices for financially integrating behavioral health
- Fierce Pharma Asia—Summit’s surprise interim trial miss; UCB’s $2B Candid buy; J&J’s CAR-T cuts
- Amazon Pharmacy to offer home delivery for Novo Nordisk's Ozempic pill
- New York expands behavioral health data access in EHRs
- Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
- New Hampshire to receive $29.5M in Purdue opioid settlement
- Behavioral health leaders counter HHS ‘overprescribing’ narrative
- Clover Health's MA membership grows 51% year-over-year
- New Study Suggests The Brain Can Continue Learning While In An Unconscious State
- Health Tech Weekly Rundown: Tether rolls out medical AI for phones, wearables; Medaptus launches operational ‘command center’
- Pennsylvania sues Character.ai over AI chatbot allegedly presenting itself as licensed medical professional
- Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
- FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
- Every 1,000 Steps After Surgery Cuts Complication Risk, Study Finds
- Bullying and Politics Fuel Suicide Risk for LGBTQ+ Teens and Young Adults, Survey Finds
- Head Impacts May Disrupt Gut Health Even Without Concussion
- Class of Migraine Drug, CGRP Inhibitors, Has Added Benefit: Reduced Glaucoma Risk
- States Eye Aid to Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- That Discount at the Pharmacy Counter May Pack Hidden Costs
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
- Hims & Hers debuts its first AI care agent to interpret biomarker lab results
- Alnylam rebuked by FDA over efficacy claims on Amvuttra website
- Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive
- Oscar Health's profit hits $679M, membership rises in Q1
- Joint Commission, NACHC partner on training, new accreditation for community health centers
- Ardent Health touts outpatient growth, checked labor spend during hectic Q1
- FDA Authorizes Fruit-Flavored Vapes for Adults
- Sanofi asks to pull Tzield bid from FDA's controversial CNPV program: report
- FDA rolls out 1-day assessment pilot in bid to refocus inspection resources
- Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs: Business Group on Health
- Edibles + Alcohol Combo Poses Driving Risks Missed by Sobriety Tests
- Leapfrog Group's latest safety grades have far fewer low scores since removal of non-participating hospitals
- VR Training Helps Autistic People Navigate Police Encounters
- Novo CEO cites pricing 'sweet spot' as Wegovy pill debuts with $355M quarter
- Weight Loss Surgeries Fall More Than 20% As Patients Turn To GLP-1 Meds, Experts Say
- FDA blocks publication of COVID, shingles vaccine safety studies: NYT
- Bayer diagnoses how to build trust in cell and gene therapies
- Amwell boasts higher than expected renewals, retention despite Q1 revenue decline
- First Psych Ward Stay Signals Long-Term Mental Health Struggles For Nearly All Patients
- Why Melatonin Shouldn't Be A Bedtime Go-To For Kids
- Children Living Near Gas Stations Have Higher Cancer Risk, Study Finds
- The timing is right for psychedelics manufacturer Optimi Health's IPO
- HHS' Healthy Food Agenda Puts Hospitals On Notice About Patients' Meals
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support
- Inside the gaps in fertility and surrogacy systems
- CVS execs say company on track to meet MA margin goals by 2028
- Facilitating Access to Trump Accounts
- Fixing Failures to Communicate
- Hinge Health lifts 2026 outlook after strong Q1 as it expands to new conditions
- For nonprofit hospitals, pricey management consultants haven't yielded better performances: study
- Supreme Court Issues Stay, Keeping Abortion Pill Mifepristone Available by Mail For Now
- Statement on Proposing Release for Semiannual Reporting
- Quarterly Questions: Statement on the Proposed Amendments to Allow Semiannual Reporting
- Statement on Proposing Semiannual Reporting
- Wellstar partners with BD to implement AI-driven medication management system
- Listen to the Latest ‘KFF Health News Minute’
- Newer Migraine Drugs Reduce Headache Days With Fewer Side Effects
- New Drug Combo Effective Against Treatment-Resistant IBD, Trials Show
- New Warning Labels Might Help People Cut Back On Drinking
- Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds
- US on the Brink of Losing Measles-free Status, Study Warns
- Delays in Visa Program Threaten Doctor Placements in Underserved Areas
- States Eye Aid To Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- Supreme Court Puts Brakes on Abortion Pill Restrictions
- FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib
- Online Misinformation Adding To Americans' Skin Cancer Risk, Survey Finds
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Social Media Videos, Easy Access Raise Risk of Teen Inhalant Use
- Staff Statement Regarding Pooled Employer Plans
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- 'Fitspirational' Posts Can Be More Harmful Than Motivational, Review Concludes
- Parents’ Stress Tied to Children’s Mental Health, New Survey Finds
- Surgeon Multitasking Increases Death Risk Of Organ Transplantees
- When Natural Disasters Strike, Another Crisis Hits Those Recovering From Opioid Addiction
- FDA Recalls Several Ghirardelli Powdered Beverages Over Potential Contamination
CCHFreedom reports the FDA trial no one else wants to touch in the US Court of Appeals for the Fifth Circuit in Louisiana.
From this week's newsletter.
Curious to know if these plaintifs are part of Front Line Docs.
FDA on Trial for Deadly Ivermectin Lies
FDA Claims Scientific Evidence Not Required to Make “Scientific” Claims
The FDA is rightly on trial for their deadly actions related to ivermectin. This quick 49-minute court hearing on August 8, 2023 — Apter vs. HHS, filed by Drs. Apter, Bowden, and Marik — was instructive and astonishing.
Several times, the judges had to insist that the FDA’s attorney, Ashley Cheung Honold, answer a question rather than obfuscate.
As Jared Kelson, the attorney for the three physicians (plaintiffs) said, “The fundamental issue in this case is straight forward.” He noted that nearly 40% of prescriptions prescribed in the U.S. are for off-label use and said: “After the FDA approves a human drug for sale, does it then have authority to influence or interfere with how the drug is used within the patient-doctor relationship? The answer is no.” He further stated that Congress prohibited it.
But the FDA’s attorney, who carefully referred only to ivermectin for animals as though that will exempt them from the impact their statements had on availability of ivermectin for humans, made several astonishing claims:
JUST HAVING FUN: The FDA’s “You’re not a horse…Stop it” tweet was “merely quips.”
NOT A COMMAND: “In some contexts those words could be construed as a command, but in this context where FDA was simply using these words as a quippy tweet meant to share its information article, those words do not rise to the level of a command.”
NO SCIENTIFIC PROCESS: Regularly claimed to the judges that scientific analysis of ivermectin had been performed but then admitted, “I don’t think there’s anything in the record that specifically tracked FDA’s process.”
NOT YOUR BUSINESS: “It’s not the role of the court to police the statements of an agency charged by Congress with making sure that drugs are safe or effective.” [Since ivermectin is safe and effective, why not say so?]
ROGUE: When challenged about the FDA’s authority to give its views, whether scientifically tested or not, “There’s nothing in the multiple sources of authority that I’ve cited that require FDA to go through any formal process.”
MEDICAL ADVICE: “No, your honor, the government is not conceding [that it cannot give medical advice]…It is not only permissible, but it is imperative that the FDA be able to inform the public about their scientific view about safe uses of drugs.”
WE HAD NOTHING TO DO WITH IT: When asked if FDA had obligation to speak up when hearing that hospitals and pharmacies were denying ivermectin based on FDA’s statements: “No, your honor, those hospitals and pharmacies are sophisticated independent third parties who are not controlled by the FDA.”
COURT HAVE NO ROLE: When asked who should hold FDA accountable if courts can’t: “The public can elect its government officials and FDA like other government agencies have politically accountable heads of the agency who are held accountable by the political process. It’s not the role of the courts to fact-check the FDA’s scientific statements meant to further their mission to protect the public from dangerous use of this drug.”
If the judges’ questions are any indication, the physicians will win in this case. Stay tuned. I expect this case to be appealed, whatever the decision. To hear the FDA’s attorney making these audacious claims of authority and innocence, start at the 17:30 minute mark.Good News on Ivermectin Safety
The FDA knew how safe ivermectin was. And now, a first-ever study verifies thesafety of ivermectin. An April 2023 study of ivermectin poisoning out of Cameroon found that a young woman trying to commit suicide took 400 pills of ivermectin (3 mg/each), which is about 100 times the recommended dose. Her neurological and gastric symptoms were treated at the hospital for five days and she was released. She has passed the baccalaureate test and entered the university.
Full newsletter, internal link to the trial video, and more information about CCHF here.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.













